Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Bactiguard, Audiocast, Q1'26

By Inderes4/23/2026, 9:00 AM
Bactiguard

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Christine Lind
00:01 - 07:31

Thank you, operator, and welcome, everyone, to the Bactiguard presentation of the first quarter of 2026. Patrick and I will go through the presentation together today. I'll start with an overview of the quarter and our strategic progress. And Patrick will then walk you through our financials in more detail. We will, of course, open up for questions at the end. The title of today's presentation is Building Momentum Through Partnerships, Regulatory Progress, and Organizational Strength. And that reflects how we view this quarter, not driven by a single event, but by continued execution across several areas that are important for Bactiguard's long-term development. I'm actually joining you today from the US, where the Heart Rhythm Society meeting starts in Chicago later today. And with that, let me start with a high-level overview of the quarter. Next slide please. Starting with the key figures and highlights from a financial perspective, we delivered continued profitability with adjusted EBITDA of 4.9 million SEK, and reported revenues were lower compared with the same quarter last year, and we will come back to the underlying drivers behind that as we move through the presentation. Strategically, however, the quarter has been an important one. We saw increased sales of Bactiguard coated products across our collaborations, and BD has initiated sales of the Bactiguard coated Foley in parts of Europe, marking another step in expanding the reach of our technology. This was also the first reported quarter under the updated business setup with Zimmer Biomet that we announced in late December, and which has been an important transition point for that partnership. During the quarter, we also continued to invest in regulatory-related activities, which are critical for supporting both existing partners and future collaborations, and we delivered a solid performance in our Wound Management portfolio, with Hydrocyn aqua continuing to be the main driver overall. This reflects the steady execution of our strategy, even in a quarter where reported numbers continue to be impacted by external factors such as currency. Next slide please. Our focus remains on a defined set of strategic therapeutic areas: orthopedics, vascular access, cardiology, neurology, and urology. These are areas where the unmet medical need is clear and where our technology has the potential to deliver both clinical and commercial value. During the quarter, we maintained a high level of engagement across all of these areas. These include early stage discussions with potential partners, work in application development areas, and technical evaluations, again with potential partners. An important part of this engagement has been our presence at multiple international congresses, where we meet with potential partners and with clinicians in the field. These interactions have been critical for building relationships, understanding our potential partners' needs, and validating where our infection prevention technology can create the most value, thus allowing us to initiate meaningful discussions with potential relevant partners. And this is one of the reasons why I am in Chicago, as it takes typically several years from development to commercialization. We should not expect all of these early-stage activities to translate into significant short-term revenues, but they are essential for building a pipeline that supports our long-term growth in our licensed business. Next slide, please. Turning now to our partnership with BD. This is a long-standing relationship that continues to evolve and expand the reach of BD Bactiguard coated Foley catheters into new markets during the quarter. Sales of the Bactiguard coated urinary catheters began in parts of Europe, and preparations are ongoing for further expansion into additional markets. A key element of this expansion is our close operational collaboration with our partner BD during the quarter. Bactiguard teams have been involved in training and support activities together with BD, particularly for new markets. This includes project education, technical training and support for both distributors and BD sales organizations to ensure that the clinical value of the coated Foley catheters is clearly understood. These activities are an important part of how we work with partners across the entire value chain, not only licensing our technology, but also actively supporting successful market introductions. While revenues from the BD partnership were lower in the quarter compared with last year, the underlying momentum remains positive, and we continue to see in-market unit sales growth of Bactiguard coated Foleys. The partnership is strategically important for both of us, and we continue to see long-term potential as additional markets come online. Moving on to Zimmer Biomet, as mentioned earlier, this quarter represents the first reported period under the updated business setup for the ZNN Bactiguard Trauma Nail system. The focus during the quarter has been on two main activities: first, advancing the MDR transition in Europe, which is a necessary step to ensure continued and expanded commercialization under the current regulatory framework; and secondly, continuing post-market clinical studies. These studies are also critical for strengthening the clinical evidence base and supporting future commercial developments. While this exciting phase in the Zimmer Biomet Partnership is about building the foundation more than delivering immediate volume growth, it is an important step towards increasing transparency and predictability in our revenues over time. Beyond the operational progress, I want to emphasize that the collaboration with Zimmer Biomet remains constructive and forward-looking, with a shared commitment to strengthening the clinical and regulatory position of Bactiguard coated trauma implants as a meaningful pillar in the Zimmer Biomet infection prevention category. Next slide please. Turning to Wound Management, the portfolio delivered a solid performance in the quarter, with Hydrocyn aqua continuing to be the main contributor. While suture sales are now stabilizing. Revenues were lower compared with the strong first quarter last year due to timing effects of certain tenders in certain markets, but the underlying development does remain positive. During the quarter, we continued onboarding distributors entering new markets and received encouraging feedback related to both demand and clinical relevance of our products across both our existing and our new markets. We also continued activities related to MDR for this portfolio as well, and ensuring that the portfolio is well positioned to support future growth, as Wound Management remains an important, complementary part of the Bactiguard portfolio, providing diversification and opportunities to apply our infection prevention expertise in additional areas. And with that, I will hand back to Patrick, who will take you through the financials in more detail.

Patrick Bach
07:34 - 14:18

Thank you very much, Christine. For Q1, we report lower revenues while continued EBITDA profitability and positive momentum across our businesses despite timing effects. In short, we deliver an adjusted EBITDA of 4.9 million and a margin of approximately 11% versus 15% last year, explained by a lower revenue quarter, notably on BD due to timing effects. Total revenue decreased 16%, excluding currency effects. While the full reported revenue amounted to 46.9 million for the quarter. Our net sales were down 17% excluding currency, and reported at 42.4 million for the quarter. For both license and Wound Management, we report lower revenues versus our first quarter last year, partly due to timing effects. While we do see positive momentum across our businesses and customer relations for our license business, we report a decrease of 20% excluding currency in a total reported revenue of 25.1 MSEK, again driven by lower BD revenues. While we reported higher revenues on Zimmer Biomet. Looking closer at the wound management portfolio, we saw a decrease in revenues of about 8% for the first quarter, excluding currency effects, against a very high base of last year. In this quarter, we continue to see strong underlying growth for Hydrocyn aqua. In addition, we also see a positive stabilization within sutures. We continue to see great demand for our portfolio and onboarding of new partners and distributors in attractive markets. And our expectation is still that the Wound Management portfolio will deliver double-digit growth going forward. Now, looking closer at our core business, we saw license partner revenues decreased by 22%, excluding the currency effects, and reported at 24.2 million. Obviously notably down for this quarter driven by BD. While Zimmer Biomet revenues were reported higher than last quarter. Looking at BD, we saw revenues coming in 16% lower than last quarter, when we exclude the currency effects, and reported at 21.1 million. While we see positive momentum at BD across all markets, as Christine mentioned, we did see notably lower shipments of our concentrate to BD in this quarter alone, as this constitutes the majority of our revenues in the isolated quarter. This obviously affected our results. We see, however, positive continued growth on the actual royalties on sell-out volumes of Bactiguard coated catheters across BD markets, and in fact, we observed the second highest royalty amount from BD over the last three years, with the highest amount in fact being our most recent Q4. So this supports our continued view on a positive and growing partnership with BD, and we are excited and busy about collaborating on future launches in 2026. On Zimmer, we reported Q1 revenues of 4.1 million, which represents our new mutual agreement on the ZNN Bactiguard nail system announced in December and our continued partnership; overall, across our partnerships, we see continued positive in-market volume growth for both BD and Zimmer, and we see additional future demand for customers and clinicians for our technology. On our operating expenses, we continue to demonstrate diligent cost control. In Q1, our total OPEX was 39 million, approximately an 8% decrease compared to Q1 last year, while reducing costs and complexity. While doing so over the last year in particular, we have at the same time continued to invest in our business, including strengthening of the organization, which Christine also has mentioned. While we do continue to exercise cost control, we do not expect continued reductions on personnel costs. However, we do expect small reductions on other external expenses going forward. As mentioned, despite a decline in revenues, we continue to deliver positive EBITDA profitability with 4.1 million for the quarter in EBITDA and 4.9 million in adjusted EBITDA. The reduction in profitability is driven by lower revenues, as mentioned, while our continued cost control and scaling our licensed business enables us to continue to deliver positive results. Our adjusted EBITDA reflects non-recurring external MDR costs, which we have expected for this quarter and continue to expect in the coming quarters. Our operating result for Q1 amounted to -7.2 million versus the 2.6 million last Q1, and our net result was -5.6 million versus the 4.7 million last year. Looking at cash flow, we see total cash flow for the period of approximately 10 million and operating cash flow of about-7.4 million. This was driven by a change in working capital and while being negative, it was an improvement versus our first quarter last year. And all in all, total cash at the end of Q1 amounts to 35 million Swedish kronor. With that, back to you, Christine.

Christine Lind
14:21 - 14:52

Thank you Patrick. I want to communicate that factors impacting our financial results this quarter do not change our strategic direction or the underlying fundamentals of the business. And our targets for 2030 are unchanged. We remain focused on strengthening our partnerships, advancing our regulatory pathways and building long-term value through disciplined execution across our portfolios. And with that, I would like to open up for questions.

Operator
14:54 - 15:11

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Christopher Lilleberg from DAB Carnegie. Please go ahead.

Christopher Lilleberg
15:13 - 15:56

Yeah. Hi. A couple of questions. First, on this lower BD revenues in the quarter. You talked a little bit about it, but is it possible to split? How much of BD sales typically is royalty versus product sales? And then the low product sales you highlighted in the quarter, would you say that you ship below trend in this first quarter, or was it so that you were above trend? in the second half of last year. Yeah, that's the first question.

Patrick Bach
15:58 - 18:13

Thank you for that. In general, we have two main drivers of our revenues with BD. The vast majority comes from the concentrate sales that we ship to BD. We ship that every single month. We are, of course, subject to changes in their ordering pattern of our technology, which is a raw material into their supply chain process. What we see in the royalties is that we see positive growth on BD sell out in all markets. And as I mentioned, we do in fact see the second largest royalty over the last three years, with the largest royalties being actually our last Q4. So this means what we see from BD is actually that the sell out of the Bactiguard coated catheters in BD markets continues to be positive in this quarter alone. As we've stated, we see a total revenue from BD being significantly lower. And this is due to the lower amount of concentrate that we have shipped. So this obviously affects our reported revenues for this quarter alone. As we have seen historically. Their ordering patterns change. We're not in full control of this, obviously. And we saw high ordering patterns obviously during 2024, and in the recent quarters, we've seen a bit lower ordering patterns. This doesn't change our view and our visibility to the positive growth in the BD sales of Bactiguard coated catheters in the markets.

Christopher Lilleberg
18:18 - 18:32

Based on the royalty trend, would you say that the current run rate for total BD sales is more aligned with, or a more fair level than, what you saw in maybe the third and fourth quarter last year?

Patrick Bach
18:34 - 19:26

Yeah. So I think we have mentioned that the sell-out volume for BD, on which royalties are based, the visibility we have here, Christopher, is the same positive mid-single-digit growth numbers that we have mentioned before. So technically there is no big shift in that. So that remains positive. I think we spoke about in the recent quarters as well that while we saw very high double-digit growth on BD sales in 2024 and in the beginning of 2025, where we had Q1 2025 as probably the last very high quarter for BD. This is obviously not translated into market growth in the same inherent quarter.

Christine Lind
19:30 - 20:21

Hi, Christopher. This is Christine. If I can just complement what we see going forward, which I hope is a good complement to Patrick's answer on what we see looking back. I think, as we had indicated before as well, since there was a delay in the regulatory approvals, especially for the European markets with the CE mark, which was a delay versus what both BD and we had expected together. It does mean that they had ordered concentrate or some stock in anticipation of launches. So now, of course, we are seeing the benefit of the information we provided in Q4 that they now have the approvals in place to be able to have and initiate sales in Europe. And we now see that going forward, BD has started sales of the Bactiguard-coated Foley catheters in parts of Europe.

Christopher Lilleberg
20:24 - 20:47

Okay. Thanks. And my second question is. So looking at the total revenues from BD and Zimmer that you report, that's tied to the license partner sales. Is it possible to specify the development revenue you had in the quarter, which I believe was 1 million or so? Is that related to BD or Zimmer?

Patrick Bach
20:50 - 21:17

I think we can say that that is related to Zimmer. And that's historically, we do have revenues with Zimmer that have been split across basically the three revenue buckets we have in this quarter. You're absolutely correct. We do report Zimmer revenues split into two of the buckets, both the licensed partner revenues and the application development revenues.

Christopher Lilleberg
21:20 - 21:21

Okay. Thank you.

Patrick Bach
21:21 - 21:22

Yeah.

Operator
21:25 - 21:39

As a reminder, if you wish to ask a question, please dial pound key five on your telephone keypad. As a reminder, if you wish to ask a question, please dial pound key five on your telephone keypad. The next question comes from Mattias from Seb. Please go ahead.

Christopher Lilleberg
21:43 - 21:43

Hi.

Mattias
21:49 - 21:51

Sorry. This is Mattias.

Christine Lind
21:52 - 21:54

Yes, we hear you, Mattias.

Mattias
21:55 - 22:32

Oh. That's great. Hi. Thanks for taking my questions. First, you highlight the changes in the leadership team in the CEO letter. I don't know if you could elaborate maybe a little bit further on the workforce of Bactiguard and focus perhaps on the license sales. So how many are dedicated to ensuring new deals flow in the coming years? And how does the team engage to make this happen? And has this changed in line with the new research strategy? Just to get some further understanding. That's the first one.

Christine Lind
22:33 - 24:40

Thanks, Mattias. Yes, indeed. As we indicated, we have decided to strengthen at the executive management level to be able to complement the capabilities that we already put in place to help support the license organization, but also the Wound Management team. So as we think about our portfolios, we've tried to strengthen the leadership team across all of those. We started last year by primarily strengthening around our existing R&D capabilities. So, having onboarded our Chief Scientific Officer and our Head of R&D, who we announced last year, and this year, we are now adding the complementary capabilities into the management team that also help us deliver value across the whole value chain to our partners. So that includes regulatory capabilities as well, and our commercial teams, both in the form of business development and alliance management. So that's directly where we work. But that also includes our commercialization activities in support of marketing and the sales training, for example, that we've mentioned we're doing with BD during this quarter and going forward. So this also represents our ability to help support our partners across the entire value chain, all the way from technology through regulatory approvals and through commercialization. So that has been an important complement. We've, of course, had these capabilities within our organization, but want to make that transparent at our senior leadership team levels. In addition, we've also brought on board during last year a leader for our wound management business, who is located in Malaysia together with our headquarters there for the wound management business. And that person is also now a part of our leadership organization so that we can also ensure that we have continued focus on growing and developing the Wound Management portfolio, especially from a commercial standpoint. So this organizational strength has been really focused on ensuring that we can drive growth in both parts of our portfolio, both for license and for wound management.

Mattias
24:42 - 24:54

Okay. So if you look at the organization, how many are working solely with finding new partnerships? Engaging in fairs and conferences and so on today.

Christine Lind
24:54 - 25:56

From a license perspective, the way we go to market here is by using complementary strength in our organization. So it's both a commercial focus team, a handful of us, including those in executive positions, especially myself, represent the commercial aspect of the organization. We're a handful of people that are solely dedicated to doing that. We also complement this with what I would call our technical sales, because, since we are co-developing our partners' products and obtaining regulatory approval, these portions of our business development activities are very important. And so our key leaders in our R&D organization, our technical organization are also a very strong part of that along with our regulatory team. So this is really an important delivery and a sale that we make across all of our different capabilities and competence areas. Because it is actually the whole that helps us deliver new partners.

Mattias
25:58 - 26:32

Okay. Thanks. And also, if you could elaborate a little bit year to date here, how dialogues have proceeded with potential new partners or in or further discussions with partners you already have today if something has happened. And also, do you see any apparent triggers coming 12 to 24 months that can improve the potential to secure a deal, like any data on the coating technology or something?

Christine Lind
26:35 - 28:20

Thanks. Great question. Yes, we do see a lot of momentum. Especially in the key therapeutic areas where we have been focusing over time. So if I just pick, for example, the orthopedics category is a very important one for us. Some of the work that we have done to reorganize how we work with Zimmer Biomet has also been an important enabler for our business development discussions with other potential partners. This is a very good category for us both from a market potential standpoint in terms of sheer size of market, but also in terms of where the unmet need is in infection prevention. And we see certainly a lot of interest for that. And we're indeed at the largest orthopedics conference as well earlier in the quarter. So this has been an important area for us to develop. And we do see a lot of interest and momentum in this category. We're also working actively across both the cardiology and the neurology categories where we do see interest in potential developments there, and indeed, the work we have started doing, which has been apparent on our pipeline page in the cardiology area, is on track. Some of this work does take a little bit longer to deliver, because there are some feasibility studies that in certain cases can extend several months to deliver the initial results that will allow us to then move forward to potential partnerships. So it does take a little bit of time for us to actually be able to deliver the deals on the other side that are apparent here. But we are very confident in the momentum across our therapeutic areas and with interest across the categories.

Mattias
28:22 - 29:01

Okay, good. One final question: Were costs again low in this quarter? So I understand that you cannot make future projections maybe on a quarterly basis. But can you talk about costs more generally, how do you look at them over the next 1 to 2 years? Should we still anticipate costs to come up as you grow the organization? Or is this more flexible with the momentum on top line and dialogues, and so on? Or can you give some color there how you think about it?

Patrick Bach
29:03 - 30:46

Yes. Thanks, Mathias, for the question. As we said over the last two years, and last year in particular, we've obviously taken out a lot of cost relating both to personnel costs and external costs. We have done so while still strengthening the organization and creating a team, which you're also speaking to, that focuses a lot more and is enabled to grow the license business. As we look forward, we do not see or plan any significant reductions in cost on the people side. We have a strong team today. And as Christine has said, we will continue to strengthen where needed. But we have established the team that we are today on the external side; we will continue to demonstrate cost control and to take out cost where we can. But as we've said previously, we will continue to invest in the business and do what we think is right for the long term. And we will maintain our focus on EBITDA profitability. So, I guess what we're saying here is that we do not see further reductions on people cost. We expect slight reductions on external expenses, but we keep our focus on our EBITDA profitability.

Mattias
30:49 - 30:51

Okay. That was all for me. Thank you.

Patrick Bach
30:53 - 30:54

Thank you.

Operator
30:55 - 31:12

There are no more phone questions at this time. So I hand the conference back to the speakers for any written questions and closing comments. There are no more phone questions at this time. So I hand the conference back to the speakers for any written questions and closing comments.

Christine Lind
31:17 - 31:36

Okay. Thank you, everyone for joining us today. I can see that there are no further questions. Thank you for the thoughtful questions that we've received today and for your continued interest in Bactiguard. We appreciate our dialogue, and we look forward to continuing to update you on our progress in the coming quarters. Thank you for today.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…